Ig Vena

Human Normal Immunoglobulin, the active ingredient in Ig Vena, is an Immunoglobulin presented as a solution for injection for intravenous use. It provides passive immunity and is employed to treat primary and secondary immunodeficiency diseases, immune thrombocytopenia, Kawasaki disease, and to support patients undergoing bone marrow transplantation.

GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets through robust cold‑chain logistics and validated manufacturing processes.

Ig Vena (Human Normal Immunoglobulin) is used in immune‑mediated conditions and immunodeficiency disorders to restore IgG levels.

- Primary immunodeficiency diseases: replaces deficient IgG, reducing infection frequency and severity. - Secondary immunodeficiency (e.g., chemotherapy‑induced): provides passive immunity to protect against opportunistic infections. - Idiopathic thrombocytopenic purpura (ITP): modulates immune response, helping raise platelet counts. - Kawasaki disease: reduces inflammation and coronary artery complications in acute phase. - Bone marrow transplantation: supports immune reconstitution and infection prophylaxis post‑transplant.

Ig Vena may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache occurring during or after infusion. - Fever or chills: transient temperature rise or shivering. - Nausea: mild gastrointestinal upset. - Fatigue: temporary tiredness post‑infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Thromboembolic events: clot formation in veins or arteries. - Acute renal failure: sudden loss of kidney function, especially in high‑risk patients.

When administering Ig Vena, clinicians should observe several precautions to minimize risks. - Assess patient history: evaluate prior reactions to immunoglobulin products. - Monitor infusion: observe vital signs and symptoms throughout administration. - Adjust rate for high‑risk patients: slower infusion may reduce adverse events. - Hydration status: ensure adequate fluid intake to support renal function. - Concomitant medications: review anticoagulants or immunosuppressants for interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may diminish vaccine efficacy; avoid concurrent administration. - High‑dose aspirin or NSAIDs: increase risk of bleeding when combined with anticoagulants. - Rituximab: may reduce IgG levels, compromising therapeutic effect.

Moderate Interactions (Monitor Closely): - Corticosteroids: may augment immunosuppressive effects, requiring dose adjustment. - Diuretics: can affect fluid balance, monitor renal function. - ACE inhibitors: watch for potential renal impairment when combined.